AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Citi Upgrades Bio-Techne to Buy from Neutral with $70 Price Target
ByAinvest
Thursday, Aug 21, 2025 8:49 am ET1min read
Citi upgraded Bio-Techne (TECH) to Buy from Neutral with a price target of $70, up from $55. The firm views the company's growth and margin outlook as conservative, and believes the stock is undervalued at current levels. Easing tariffs, growth in China, and margin expansion are expected to drive upside to Bio-Techne's guidance.
Citi has upgraded Bio-Techne (TECH) to a "Buy" rating from "Neutral," with a new price target of $70, up from $55. The firm expects the company's growth and margin outlook to remain conservative, but believes the stock is undervalued at current levels. Easing tariffs, growth in China, and margin expansion are anticipated to drive upside to Bio-Techne's guidance [1].The upgrade comes amidst a positive quarter for Bio-Techne, which reported better-than-expected fourth-quarter revenue and profit, driven by strong demand for its proteins, antibodies, and other research products [2]. The company also announced a strategic partnership with Spear Bio to distribute its next-generation immunoassays, further bolstering its growth prospects [3].
Citi's optimism is supported by recent market trends, with the S&P 500, NASDAQ Composite, and Russell 2000 Indices rebounding in the second quarter of 2025, driven by better-than-expected earnings and renewed optimism surrounding AI growth [4]. The technology sector, in particular, led the charge, with AI-related gains in semiconductors and strong performances from software and hardware companies [4].
However, investors should remain cautious, as trade tensions and geopolitical uncertainties continue to pose risks to the market [4]. Additionally, Bio-Techne's recent acquisition of Exosome Diagnostics Inc. and its ongoing divestiture of the business could introduce operational complexities [5].
References:
[1] https://stockanalysis.com/stocks/tech/
[2] https://seekingalpha.com/article/4814900-macquarie-mid-cap-growth-fund-q2-2025-commentary
[3] https://prnewswire.com/news-releases/bio-techne-corporation-and-spear-bio-announce-strategic-partnership-to-advance-therapeutic-development-with-ultrasensitive-biomarker-detection-301212074.html
[4] https://prnewswire.com/news-releases/bio-techne-corporation-technologies-utilized-in-recent-fda-approval-of-zevaskyn-cell-based-gene-therapy-301212074.html
[5] https://prnewswire.com/news-releases/bio-techne-announces-exosome-diagnostics-divestiture-301212074.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet